X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (66) 66
male (62) 62
female (57) 57
chemistry (56) 56
metallurgy (56) 56
aged (52) 52
index medicus (51) 51
oncology (48) 48
middle aged (46) 46
adhesives (42) 42
dyes (42) 42
miscellaneous applications of materials (42) 42
miscellaneous compositions (42) 42
natural resins (42) 42
paints (42) 42
polishes (42) 42
chemical paint or ink removers (41) 41
coating compositions, e.g. paints, varnishes orlacquers (41) 41
correcting fluids (41) 41
filling pastes (41) 41
inks (41) 41
pastes or solids for colouring or printing (41) 41
use of materials therefor (41) 41
woodstains (41) 41
lung neoplasms - drug therapy (37) 37
chemotherapy (36) 36
lakes (33) 33
mordants (33) 33
organic dyes or closely-related compounds for producing dyes (33) 33
adult (31) 31
carcinoma, non-small-cell lung - drug therapy (30) 30
cancer (26) 26
treatment outcome (26) 26
lung cancer, non-small cell (25) 25
lung neoplasms - pathology (23) 23
aged, 80 and over (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
lung cancer (22) 22
non-small cell lung cancer (20) 20
respiratory system (20) 20
apparatus therefor (19) 19
research (19) 19
care and treatment (17) 17
electricity (17) 17
analysis (16) 16
lung neoplasms - mortality (16) 16
physics (15) 15
disease-free survival (14) 14
docetaxel (14) 14
after-treatment of single crystals or a homogeneouspolycrystalline material with defined structure (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
basic electric elements (13) 13
carboplatin (13) 13
chemical surface treatment (13) 13
cisplatin (13) 13
coating by vacuum evaporation, by sputtering, by ion implantationor by chemical vapour deposition, in general (13) 13
coating by vacuum evaporation, by sputtering, by ionimplantation or by chemical vapour deposition, in general (13) 13
coating material with metallic material (13) 13
coating metallic material (13) 13
crystal growth (13) 13
diffusion treatment of metallic material (13) 13
electric solid state devices not otherwise provided for (13) 13
inhibiting corrosion of metallic material or incrustation ingeneral (13) 13
medicine & public health (13) 13
neoplasm staging (13) 13
production of a homogeneous polycrystalline material withdefined structure (13) 13
refining by zone-melting of material (13) 13
semiconductor devices (13) 13
single crystals or homogeneous polycrystalline material withdefined structure (13) 13
single-crystal-growth (13) 13
surface treatment of metallic material by diffusion into thesurface, by chemical conversion or substitution (13) 13
survival rate (13) 13
unidirectional solidification of eutectic material orunidirectional demixing of eutectoid material (13) 13
carcinoma, non-small-cell lung - mortality (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
clinical trials (12) 12
gefitinib (12) 12
hematology, oncology and palliative medicine (12) 12
antineoplastic agents - therapeutic use (11) 11
general tagging of cross-sectional technologies spanning over several sections of the ipc (11) 11
general tagging of new technological developments (11) 11
multicenter (11) 11
open-label (11) 11
performing operations (11) 11
pulmonary/respiratory (11) 11
technical subjects covered by former us classification (11) 11
technical subjects covered by former uspc (11) 11
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (11) 11
therapy (11) 11
transporting (11) 11
blasting (10) 10
follow-up studies (10) 10
heating (10) 10
lighting (10) 10
mechanical engineering (10) 10
oncology, experimental (10) 10
weapons (10) 10
antineoplastic agents - adverse effects (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
colour printing (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 04/2018, Volume 109, Issue 4, pp. 1177 - 1184
Osimertinib is a potent, irreversible epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ) selective for EGFR ‑ TKI sensitizing ( EGFR... 
cytology | T790M | epidermal growth factor receptor | non‐small cell lung cancer | osimertinib | non-small cell lung cancer | 1ST-LINE TREATMENT | ACQUIRED-RESISTANCE | FOLLOW-UP | EGFR MUTATION | OPEN-LABEL | CHEMOTHERAPY | CLINICAL-PRACTICE GUIDELINES | RANDOMIZED PHASE-3 TRIAL | SPECIMENS | ONCOLOGY | ERLOTINIB | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | ErbB Receptors - genetics | Male | Mutation - genetics | Piperazines - pharmacology | Disease-Free Survival | Asian Continental Ancestry Group | Mutation - drug effects | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Medical research | Care and treatment | Development and progression | Lung cancer, Small cell | Lung cancer, Non-small cell | Complications and side effects | Epidermal growth factor | Analysis | Medicine, Experimental | Skin | Diagnosis | Cancer | Plasma | Peptides | Epidermal growth factor receptors | Research funding | Lung cancer | Cytology | Stockholders | Diarrhea | Non-small cell lung carcinoma | Cancer therapies | Patients | Disease control | Studies | Acids | Cellular biology | Biopsy | Mutation | Protein-tyrosine kinase | Tumors | Original
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 1, pp. 42 - 50
Journal Article
Journal Article
Nihon Naika Gakkai Zasshi, ISSN 0021-5384, 06/2017, Volume 106, Issue 6, pp. 1108 - 1116
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3248 - 3257
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 194 - 200
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 08/2015, Volume 42, Issue 8, pp. 944 - 951
Journal Article